Piper Sandler analyst Biren Amin initiated coverage of Centessa (CNTA) with an Overweight rating and $38 price target The company is developing a multi-asset orexin receptor 2 agonist franchise to address excessive daytime sleepiness, fatigue, impaired attention, and cognitive defects across neurodegenerative and neuropsychiatric disorders, the analyst tells investors in a research note. The firm believes orexin agonists “have wide reaching potential.” Centessa’s ORX750 is a potential best-in-class OX2R Agonist and the upcoming Phase 2a data in 2025 “represents a major catalyst,” contends Piper.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa Pharmaceuticals: Promising Potential in Neuropsychiatric Disorders with ORX750 and Orexin Agonist Pipeline
- Centessa Pharmaceuticals: Promising Orexin Pipeline and Strong Financials Drive Buy Rating
- Promising Potential of Centessa Pharmaceuticals’ Orexin Agonist Pipeline Drives Buy Rating
- Centessa Pharmaceuticals Advances OX2R Agonist Pipeline
- Centessa Pharmaceuticals’ ORX750: Promising Phase I Results and Market Potential Justify Buy Rating